EuBiologics announced on the 2nd that its second factory located in Chuncheon, Gangwon Province, has received prequalification (PQ) approval from the World Health Organization (WHO) for the production of the oral cholera vaccine 'Euvichol-S'.
Previously, EuBiologics' second factory also obtained WHO PQ approval for the production of the oral cholera vaccine 'Euvichol-S' concentrate in April of last year. In February, it also received approval from the Ministry of Food and Drug Safety for the manufacturing quality management standards (GMP) for finished goods.
As a result, the company expects to produce a maximum annual output of 80 million to 90 million doses of the cholera vaccine by mass-producing concentrates and finished goods at both factories. It is projected to exceed the UNICEF supply target of 72 million doses this year.
A company official noted, 'The second factory has established a full-operation system by producing not only the current main product, the oral cholera vaccine, but also concentrate production for follow-up development products such as typhoid conjugate vaccine, meningococcal conjugate vaccine, and the Contract Manufacturing Organization (CMO) business for bacterial vaccine concentrate production.'